Becker's Healthcare October 9, 2025
The FDA has approved cemiplimab-rwlc, marketed as Libtayo, as the first immunotherapy for adjuvant treatment of cutaneous squamous cell carcinoma with a high risk of recurrence after surgery and radiation.
Tarrytown, N.Y.-based Regeneron Pharmaceuticals received approval Oct. 8 following a priority review. The decision...







